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C L I N I C A L  R E S E A R C H  S T U D I E S
Chronic obstructive pulmonary disease (COPD) is a 
disease which is characterized by a progressive, partial re-
versible bronchial obstruction, which results from airway 
inflammation in response to unfavorable external factors 
(smoking, occupational hazard, pollutants and others).  It is 
established that in cases of COPD, morphological changes are 
observed in the central and peripheral branches as well as in 
the lung parenchyma.  The result of epidemiological research 
shows that in Europe and North America 4 – 15% of the adult 
population suffers from COPD [1, 2].  Official data show that 
in the Russian Federation 2.4 millions patients with COPD are 
registered.  But the data from epidemiological research leads 
us to believe that this number could be as high as 16 millions 
people [3].  The morbidity and the mortality of the patients 
with COPD increases all over the world, which is primarily 
related to a high smoking rate.  It is shown that this disease 
affects 4 – 6% of males and 1 – 3% of females older than 40 
years [4].  In Europe this is for the cause of death of 200-300 
thousands people per year [1, 3].
Exacerbation is a stage of COPD course.  It negatively 
affects the quality of a patient’s life, leads to the progression of 
bronchial obstruction, and is often a cause of hospitalization 
that considerable increase to the cost of treatment. COPD 
exacerbations can also be a cause of death.  Exacerbations 
take place approximately 1 – 4 times a year [3].
Exacerbation is an acute increase of symptoms, in com-
parison with the otherwise stable state of patients.  The most 
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Abstract
In this study, new aspects of treatment of exacerbations of chronic obstructive pulmonary disease are presented based on vast clinical material and 
our own studies.  According to the obtained data it can be concluded that the treatment of chronic obstructive pulmonary disease exacerbations is a 
complex process, oriented towards a multitude of pathogenic mechanisms of the disease.  One of the pathogenic mechanisms of chronic obstructive 
pulmonary disease exacerbations is respiratory infection which makes the administration of the antibacterial drugs is an important component in the 
complex treatment of the disease.  The administration of antibacterial therapy diminishes the hospitalization period of these patients and, as a result, 
reduces the total economical impact of the health management.
Key words: chronic obstructive pulmonary disease, complex treatment, antibacterial therapy.
Лечение обострений хронической обструктивной болезни легких
В работе представлены современные аспекты лечения обострений хронической обструктивной болезни лёгких, которые основаны на 
обширном клиническом материале и на основании собственных клинических исследований.  На основании полученных результатов можно 
сделать вывод, что лечение обострений хронической обструктивной болезни лёгких представляет комплексный процесс, обусловленный 
воздействием множеством патогенетических механизмов данного заболевания.  Один из патогенетических механизмов заболевания – 
респираторная инфекция, что обуславливает назначение антибактериальных препаратов в лечении обострений хронической обструктивной 
болезни лёгких.  Дифференцированный подход к назначению антибактериальных препаратов приводит к уменьшению периода госпитализации 
пациентов и как следствие этого – к уменьшению экономических затрат при оказании медицинской помощи.
Ключевые слова: хроническая обструктивная болезнь лёгких, комплексное лечение, антибактериальное терапия.
frequent exacerbation symptoms are difficult breathing, cough 
intensification, increase in the production of expectoration 
and the changes of its characteristics.  These symptoms often 
demand a modification of the pharmaceutical treatment [2, 
3, 4].  Their mechanisms are shown in tab. 1.
The exacerbations of COPD are often associated with 
acute respiratory infections of the upper respiratory tract. We 
observed intensification of wheezing, subjective reports of 
feeling pressure in the throat, peripheral edema (appearance 
of peripheral edemas, weight’s increasing etc.), increasing of 
general weakness and disturbances of conscience.  Throat 
pain and fever normally do not appear in the exacerbations 
of COPD, but if present, other diseases have to be excluded 
(pneumonia, pneumothorax, thromboemboli of pulmonary 
arteries etc.).
The Reasons of COPD – exacerbations are:
1. Infection: H. influenzae, St. pneumoniae, M. catharralis 
which correspond to 13 – 46%, 7 – 26% and 9 – 20%, respecti-
vely.  Enterobacteriaceae fam. should be considered as a cause 
of COPD exacerbation if patients are older than 65 years, have 
concomitant chronic pathologies or if the peak expiratory 
flow (PEF) during the first second is less than 50%.  In cases 
of bronchiectasis with a permanent production of purulent 
expectoration P. aeruginosa should be considered [5].
2. Pollutant (NO2, Sulfuric dioxide, Ozone, hard particles).
3. Drugs (beta-blockers, sedatives, barbiturates etc.).
4. Cardiac insufficiency and heart rhythm disorders.
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Table 1
Possible mechanisms for the development of symptoms of exacerbations of COPD
Symptoms Mechanisms of Development Comments
1. Progression of 
shortness of breath
• Increased catabolism 
• Bronchial obstruction 
a) mucosal damage, increased bronchial hyper-
reactivity/bronchospasm 
b) the infiltration of inflammatory cells of the 
respiratory tract 
c) edema of the bronchial mucosa
d) mucous hypersecretion with increase in 
viscosity leading to formation of mucous plugs, 
reducing mucociliary clearance 
e) the progressive worsening of the diffusion-
perfusion gradient
Consequence of systemic inflammation and acidosis in COPD.
Associated with increased production of neutrophils’ proteinases, bronchial epi-
thelium endothelin-1, and colonization with bacteria (H. influenzae) and viruses.
Increase in the number of CD8+ lymphocytes, neutrophils, eosinophils; asso-
ciated with increased production of «proinflammatory» cytokines (IL-6, TNFα, 
RANTES, etc.), neurotransmitters (LTV-4) and increased expression of adhesion 
molecules (ICAM-1, E-selectin). 
It can occur by the bacteria (H. influenzae, S. pneumoniae, Ps. aeruginosa), viruses, 
pollutants .
Enhancing blood flow on poorly ventilated areas can easily lead to a deteriorati-
on of gas exchange and growth of hypoxemia.
2. Increased sputum 
production
• Hypertrophy of the mucous glands 
• Hyperplasia of goblet cells 
• Degranulation of goblet cells
Arises as a result of neutrophils’ inflammation and the action of proteases under 
various pollutants and microorganisms.
3. Appearance of 
purulent sputum • The accumulation of eosinophils and neutro-
phils
Associated with increased production of proinflammatory cytokines and 
increased expression of adhesion molecules (see above), all of which can occur 
secondary to bacterial infection.
Note: IL - interleukin (s); TNFα-tumor necrosis factor α; RANTES - regulated upon activation, novel T-cell expressed and presumably secreted 
(a molecule that is possibly secreted by activated T-lymphocytes); ICAM-1 - intercellular adhesion molecule - 1, LT-Leukotrienes.
5. Thromboemboli of a. pulmonalis.
6. Pneumothorax.
7. Undetermined reason (approx. in 30% of all cases).
Respiratory infection is the reason for approximately 80% 
of COPD – exacerbations with a determined etiology.  Often 
you can find St. pneumoniae in early and moderate stages of 
COPD (PEF1 > 50% from basic mean).  In cases of severe 
and very severe course of the disease (PEF1 < 50% from 
basic mean) – gram-negative microflora (H. influenzae, M. 
catharralis, P. aeruginosa etc.) are common.
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The mechanism through which microorganisms cause COPD exacerbations has not been well 
studied and remains unclear. It is well known that bacteria intensify the inflammation process in 
the respiratory tract in COPD exacerbations. This inflammation changes the local environment in 
the airways and increases susceptibility to formation of new colonies of microorganisms that
colonize the bronchial mucosa (H. influenzae) [6, 7, 8]. The role of microorganisms in the 
evolution of COPD is described by the hypothesis of “vicious circle”, which says that the damage 
of airways is the result of chronic infection. Meanwhile, chronic presence of pro-inflammatory 
mediators (interleukin 6, 8, TNF, leucotryen B4) decreases the efficiency of bronchial transit (fig.1).
Fig. 1. The role of microorganisms in evolution of COPD (“vicious circle” conception).
Based on the recommendations of the experts of European and American Thorax Society, we
distinguish mild, moderate and severe stages in the courses of COPD (tab. 2).
The treatment of exacerbations is as follows: broncholytics, systemic corticoids, antibiotics.
Antibacterial treatment is indicated in cases of clinical manifestations of exacerbation [5, 9].
Sputum analysis for the etiological factor isn’t specific because the respiratory tract of such patients 
is often colonized by bacteria. Sputum analysis is recommended in cases of frequent exacerbations
or in the presence of purulent expectoration when organisms resistant to traditional treatment are 
suspected.
The most common criteria for indication of antibacterial therapy were evaluated by 
Anthonisen et al. (1987) which describes three types of COPD exacerbations. The first type is 
characterized by intensification of dyspnea, increase in produced sputum volume and a change in 
the sputum characteristic, such as a purulent appearance. The second type includes two of these 
symptoms, the third – one. It is established that the antibacterial treatment is indicated in the first 
and the second types of COPD exacerbations.
Table 2
Environmental factors
(tobacco smoke, pollutants, childhood respiratory infections)
Breach of the mucociliary clearance
Airway epithelia damage Colonization of bacteria
COPD exacerbation
COPD progression Bacteria products Inflammation
Imbalance of proteases and
antiproteases
Increased activity of
proteases (neutrophil 
elastase, matrix
metalloproteinases, etc.)
It is important to know that you can also find bacteria in 
expectorations of patients with a stable course.  Investigations 
of protected bronchial biopsies of the lower respiratory tract 
show a colonization by microorganisms in approx. 30% of 
patients.
The mechanism through which microorganisms cause 
COPD exacerbations has not been well studied and remains 
unclear.  It is well known that bacteria intensify the inflam-
mation process in the respiratory tract in COPD exacerba-
tions.  This inflammation changes the local environment 
Fig. 1.  The role of microorganisms in evolution of COPD (“vicious circle” conception).
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in the airways and increases susceptibility to formation of 
new colonies of microorganisms that colonize the bronchial 
mucosa (H. influenzae) [6, 7, 8].  The role of microorganisms 
in the evolution of COPD is described by the hypothesis of 
“vicious circle”, which says that the damage of airways is the 
result of chronic infection. Meanwhile, chronic presence of 
pro-inflammatory mediators (interleukin 6, 8, TNF, leuco-
tryen B4) decreases the efficiency of bronchial transit (fig.1).
Based on the recommendations of the experts of European 
and American Thorax Society, we distinguish mild, moderate 
and severe stages in the courses of COPD (tab. 2).
The treatment of exacerbations is as follows: broncholytics, 
systemic corticoids, antibiotics.
Antibacterial treatment is indicated in cases of clinical 
manifestations of exacerbation [5, 9].  Sputum analysis for the 
etiological factor isn’t specific because the respiratory tract of 
such patients is often colonized by bacteria.  Sputum analysis 
is recommended in cases of frequent exacerbations or in the 
presence of purulent expectoration when organisms resistant 
to traditional treatment are suspected.
The most common criteria for indication of antibacterial 
therapy were evaluated by Anthonisen et al. (1987) which 
describes three types of COPD exacerbations.  The first type is 
characterized by intensification of dyspnea, increase in produ-
ced sputum volume and a change in the sputum characteristic, 
such as a purulent appearance.  The second type includes two 
of these symptoms, the third – one. It is established that the 
antibacterial treatment is indicated in the first and the second 
types of COPD exacerbations.
The characteristics of COPD exacerbations
Scientifically proven advantages of antibacterial therapy 
have been described in the research literature:
- Decrease in the duration of an exacerbation episode
- Avoidance of hospitalization.
- Decrease in duration of temporary disability.
- Prophylaxis for pneumonia.
- Avoid progression of damage to the respiratory tract.
- Increase of remission duration.
The aim of antibacterial therapy is eradication of micro-
organisms, which provoke COPD exacerbations, thereby 
decreasing symptoms manifestation and increasing the stable 
course of the disease.  The choice of drugs is made empirically, 
based on the particular course of a patient’s disease as well as 
on the known resistance profiles of specific organisms.  Dif-
ferent options of antibacterial therapy are showed in tab. 3.
In case of non-severe COPD exacerbations it is necessary 
to consider macrolides (Clarithromycin and Azythromycin) 
and beta-lactam antibiotics (Amoxycillin and Cephalospori-
nes of the second and the third generation).  Macrolides are 
very active towards Н. influenzae, Str. Pneumonia and intra-
cellular microorganisms (С. pneumoniae, M. pneumoniae). 
They have a high biological accessibility, deep penetration into 
lung tissue and into individual cells where they reach a high 
intracellular concentration.  Clinical and bacterial efficacy of 
macrolides in COPD exacerbation is about 78-98% [9].  We 
previously obtained data which prove a high efficacy of azi-
thromycin in treatment of COPD exacerbation.  The results of 
our studies showed that therapy with azithromycin contributes 
to decrease in respiratory symptoms: cough decreased by 3 
times (p < 0.001), quantity of expectoration – by 1.5 times (p < 
0.001), and dyspnea – by 2 times (p < 0.001), while night-time 
symptoms disappeared almost completely.  The regression of 
basic clinical manifestations is the common cumulative index 
which decreased by 3.2 times (p < 0.001).  In patients who took 
standard therapy, the respiratory symptoms also decreased, 
but less significantly than in the experimental group.  After a 
course of azithromycin therapy, cytosis indicators in induced 
expectoration decreased by 1.7 times, alveolar macrophages 
Table 2
Characteristics of exacerbations of COPD
Indicators
The severity of exacerbation 
Mild (Grade I) Moderate (level II) Severe (Grade III)
History
Associated diseases 
Frequent exacerbations 
Severity of COPD
+
+
Easy / moderate
+++
+++
Moderately severe / severe
+++
+++
Severe / very severe
Physical data 
Hemodynamics 
Involvement of respiratory muscles, tachypnea 
Persistence of symptoms after treatment
Stable
No
No
Stable
++
++
Stable / unstable
+++
+++
Diagnostic tests 
Evaluation of blood oxygen saturation 
The study of blood gases * 
Chest X-ray 
Clinical and biochemical blood tests ** 
Gram-stained smears and bacteriological analysis of sputum  
ECG 
Measurement of drug concentration in blood serum 
Yes
No
No
No
No****
No
If possible
Yes
Yes
Yes
Yes
Yes
Yes
If possible
Yes
Yes
Yes
Yes
Yes
Yes
If possible
Note: + is unlikely: + +probably, + + + highly likely; # diseases and syndromes associated with poor prognosis in exacerbations of 
COPD: Congestive heart failure, ischemic heart disease, diabetes, renal and hepatic failure, * including the values of PaO2, pH and 
PaSO2; **Biochemical analysis of blood include the determination of electrolytes and indicators of liver and kidney function; *** if the 
patient receives theophylline, warfarin, carbamezapine, digoxin; **** if the patient had recently received antibiotics.
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Table 3
Variants of exacerbations of COPD and the choice of antibiotic therapy
Variants of exacerbations Patient  Characteristics
Current  
microorganism
A series  
Antibacterials
Alternative  
treatment 
1. “Simple” exacerbations  
(without risk factors for microbial 
resistance to antibiotics)
Worsening of dyspnea and cough, 
increased sputum production 
with a purulent aspect. Any age, 
less than 4 exacerbations / year, 
the absence of concomitant 
diseases, FEV1 >  50% predicted
Haemophilus influenzae, 
Haemophilus parainfluenzas, 
Moraxella catarrhalis, Strepto-
coccus pneumoniae
„New» macrolides 
(clarithromycin, 
azithromycin), 2nd 
and 3rd  generations 
of cephalosporins, 
amoxicillin
Amoxicillin / clavu-
lanic acid Respirato-
ry fluoroquinolones
2.»Complicated» exacerbation  
(in the presence of risk factors for 
microbial resistance to antibiotics)
Symptoms of acute infection and 
one of the following criteria: age 
≥ 65, more than 4 exacerbations 
/ year, concomitant diseases of 
the cardiovascular system, FEF1 
35-50% of predicted, the use of 
«home» oxygen therapy, antibio-
tics in the last 3 months.
Haemophilus influenzae, 
Haemophilus parainfluenzas, 
Moraxella catarrhalis, Strepto-
coccus pneumoniae, Klebsiella 
spp, other bacteria gram-
negative. High probability 
of microbial resistance to 
β-lactams
Respiratory fluoroqui-
nolones (levofloxacin, 
moxifloxacin, and 
others), amoxicillin / 
clavulanic acid
Possible parenteral 
antibiotics and 
hospitalization of 
patients
3. Chronic purulent bronchitis  
(in the presence of risk factors  
for infection (Ps. aeruginosae) 
More than 4 exacerbations / year, 
FEV1< 35% predicted, possible 
bronchiectasis 
Same microorganisms that 
are in group 2, Pseudomonas 
aeruginosae, multidrug resis-
tant Enterobacteriaceae
Fluoroquinolones (ci-
profloxacin), β-lactams 
(ceftazidime, and other 
means piperacillin/ta-
zobactam with activity 
against Ps. aerugino-
sae)
-
decreased by 1.2 times.  The level of IL-1α decreased on the 
14-th day of treatment by 4.8 times, TNFα - by 4.5 times.  IL-8 
in blood decreased by 2.5 times.
Patients who received standard treament without antibi-
otics also had a decrease in systemic inflammatory markers, 
however this was less significant as compared to the group 
that received antibiotics.
Probably the treatment effect with macrolides is determi-
ned by it’s non-antimicrobial activity.  It is known these can 
modulate the activity of lymphocytes, modify the properties 
of trachea-bronchial secretions and decrease the intensity of 
systemic and local respiratory tract inflammation by changing 
the functional activity of neutrophils.
In recent years, fluoroquinolones with their antipneu-
mococcus activity (levofloxacin, moxifloxacin etc.) have 
been found to be comparable with macrolides in the treat-
ment of respiratory infections.  As proof of the advantages 
of fluoroquinolones are used arguments such as: a) a high 
resistance level of S. pneumoniae and Н. influenzae towards 
the macrolides which respectively corresponds to 30-50% and 
35% improvement in different countries; b) a better response 
in clinical symptoms and bacteriological eradication, a lower 
relapse rate of COPD exacerbations and decreased long-term 
need for antibacterial treatment, although the letter has not 
been consistently supported in all studies. 
Analyzing the mentioned results it is important to keep 
in mind that the local resistance of macrolides towards S. 
pneumoniae amounts to 2 - 6%.  The resistance level of 
macrolides to Н. Influenza is probably also low.  This fact 
has been proven by a high clinical efficacy of clarithromycin 
observed in patients with COPD [1, 2, 4, 7].  Most of the 
research shows the efficacy of respiratory fluoroquinolo-
nes, regardless of the stage of COPD.  It is also important 
to note that higher results in treating severe courses of the 
disease were obtained when macrolides were not used as 
first line treatment (tab. 3).
Respiratory fluoroquinolones and protected penicillins 
are indicated in “complicated” exacerbations of COPD.  The-
se are indicated when there is presence of risk factors such 
as resistance of the microorganisms towards amoxicillin or 
macrolides.  If there exists a high risk for P. Aeruginosae we 
recommend use of ciprofloxacin and beta-lactams given their 
activity against nosocomial pathogens (tab. 3). In most cases 
antibiotics are taken orally.  Duration of antibacterial therapy 
in “non – complicated” exacerbations is 5 – 7 days, in “compli-
cated” cases – 10 – 14 days until the complete disappearance 
of clinical symptoms of exacerbation [5, 9].
The dosage regimen of broncholytics is given in tables 3 
and 4.  In case of mild and severe exacerbations of COPD, 
especially in older patients, it is necessary to administer 
nebulizer therapy.
Because of the difficulties in dosage and the many side 
effects of theophylline, we suggest using these drugs as secon-
dary treatment when the inhaled broncholytics aren’t effective 
enough. However, no everyone agrees with this point of view. 
Probably the use of these drugs is possible only by respecting 
the indication rules and monitoring the concentration of 
theophylline in the blood.  The best known of this class is 
Euphyllin which contains theophylline (80%) dissolved in 
ethylenediamine (20%).  The schedule of its dosage is shown 
in tab. 4.  It is important to mention  that theophyllin has to be 
introduced only intravenously.  Theophylline administration 
over a long period of ime is contraindicated because there is 
a danger of overdose.
Systemic glucocorticoids are effective in treatment of 
complications of COPD.  These drugs decrease the conva-
lescence time and contribute to a more rapid regeneration of 
lung functions.  They are indicated together with broncho-
Nr. 3 (321), 2011
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lytics when FEV1 is < 50% from normal values.  Normally 
it is recommended 30 – 40 mg prednisone by mouth or the 
equivalent intravenous methylprendisolone dose for 10 – 14 
days.  Treatment for a longer period of time doesn’t lead to 
a higher effectiveness but increases the risk of development 
of side effects.  In the last few years’ data appeared about the 
possibility of using inhalational glucocorticoids (Budesoni-
de, introduced with nebulizers, as an alternative to systemic 
glucocorticoids in the treatment of COPD exacerbations.
Table 4
Dosage of Euphyllin by intravenous introduction
Particularities of introduction Doses
Loading dose (intravenously infused over 20 min):
For patients who didn’t get theophylline
For patients who got theophylline
240-250 mg
Introduction is 
contraindicated
Maintenance dose  
(intravenously infused over 3 – 5 h)
Smokers
Nonsmokers 
Patients with a low theophylline clearance 
0.9 mg/kg/h
0.6 mg/kg/h
0.25 mg/kg/h
Daily doses of theophylline 0.75-1.5 g
Patients with light exacerbations can be treated in an am-
bulatory setting.  Patients with moderate or severe levels of 
COPD have to be hospitalized.  Indications for directing the 
patients to specialized departments are as follows:
1. Significant increase in symptom intensity (e.g. appea-
rance of dyspnea in rest).
2. Conventional treatment is not effective.
3. Appearance of new symptoms (eg, cyanosis, peripheral 
edema).
4. Severe concomitant diseases (pneumonia, cardiac ar-
rhythmia, congestive heart failure, diabetes, renal and 
kidney insufficiency).
5. New onset of abnormal heart rhythm.
6. Older age.
7. Inability to provide adequate medical care in an outpa-
tient setting.
8. Difficulty of diagnosis.
Algorithms for treatment of exacerbations of COPD are 
shown in figures 2-4.
In severe exacerbations of COPD patients have to be hos-
pitalized in an intensive care unit, the indication for which are:
1. Severe shortness of breath, not releaved by bronchodi-
lators.
2. Impaired consciousness, coma.
3. Progressive hypoxemia (PaO2 < 50 mm Hg), hypercap-
nia (PaCO2 > 60 mm Hg) and/or respiratory acidosis 
(pH < 7.25), despite the use of oxygen-therapy and 
noninvasive ventilation. 
Criteria for patient discharge from hospital after a COPD 
exacerbation:
a) requirement for inhaled short-acting adreno-agonists 
does not exceed more than every 4 hours. 
b) the patient can ambulate on their own, eat and sleep 
without frequent nighttime awakenings from shortness 
of breath;
c) stable state for 12-24 hours;
d) stable blood gas analysis for 12-24 hours;
e) patient and responsible family members have a complete 
understanding of proper medication use;
f) there are arrangements for further observation and 
treatment at home.
In the next 4-6 weeks the patient should be re-examined by 
a doctor to evaluate adaptation to life and correct inhalation 
technique, as well as analysis of pulmonary function tests 
(PFT), blood gas or oxygen saturation (to decide if a long-
term oxygen therapy is necessary). Further treatment may 
be indicated at this time. 
Bronchodilators
β2-adrenoreceptor agonists short-acting and/or ipratropium bromide by metered dose inhalator
with large volume spacer or via a nebulizer, administered "on demand"
When failure - perhaps intravenous theophylline
Discuss the possibility of appointing long-lasting bronchodilators if the patient had not received
these drugs previously
Glucocorticoids (dose may vary) Prednisone 30 – 40 mg per os during 10 – 14 days. Discuss the 
possibility of using inhaled glucocorticoids (after completing treatment course with systemic 
steroids)
Antibiotics (by indications)
Bronchodilators
β-adrenoreceptor agonists short-acting and/or ipratropium bromide by metered dose inhaler with
large volume spacer or nebulizer, administered "on demand"
When failure - perhaps intravenous theophylline
Oxygen therapy (at SaO2 * < 90%
Glucocorticoids
Prednisolone 30-40 mg by mouth for 10-14 days
If cannot tolerate oral intake - the equivalent intravenous dose (up to 14 days)
Discuss the option of inhaled glucocorticoids by metered dose inhaler or nebulizer (after 
completion of treatment with systemic steroids)
Antibiotics (by indications)
*Sa  –  blood Oxygen saturation.
Check inhalation technique
Assess the level of education of patients
Fig. 2.  Ambulatory treatment of patients with mild exacerbations.
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Table 5
Inhalative broncholytics used for COPD exacerbation treatment
        Drug  Release form Doses
Salbutamol
(Ventholyn nebulets, Salgym, Steri-
neb-Salamolol etc.)
Solution  for nebulizers 2.5 and 5 mg/ml
Dosed aerosol with spacer (100 mcg/doses)
2.5-5 mg every 4-6 h  in regime «on demand»
2-4 inhalations every 4-6 h  in regime «on demand»
Fenoterol
(Berotec and Berotec H)
Solution  for nebulizers 1 mg/ml
Dosed inhaler with spacer (100 mcg/doses)
0.5-1.0 mg every 4-6 h  in regime «on demand»
2-4 inhalations every 4-6 h  in regime «on demand»
Ipratropium bromide  
(Atrovent, Atrovent H)
Solution  for nebulizers 0.25 mg/ml
Dosed inhaler with spacer (40 mcg/doses)
0.25-0.5 mg every 6-8 h  in regime «on demand»
2-4 inhalations every   6-8h in regime «on demand»
Ipratropium bromide  
and Fenoterol (Berodual and 
Berodual H)
Solution  for nebulizers (in 1ml 0.25 mg ipratropium bromi-
de and 0.5 mg fenoterol)
Dosed inhaler (in 1 inhaler. 20 mcg ipratropium bromide 
and 50mcg fenoterol) with spacer
2-4 mg every 6-8 h  in regime «on demand»
2-4 inhalations every 6-8 h  in regime «on demand»
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Fig. 3. Treatment of moderate exacerbations of COPD in hospitalized patients.
Oxygen therapy
Ventilatory support (non-invasive, less-invasive)
Bronchodilators
β2-adrenoreceptor agonists short-acting and / or ipratropium bromide by metered dose inhaler or
large volume spacer (2 puffs every 2 hours or via nebulizer)
When failure - perhaps intravenous theophylline
Glucocorticoids
Prednisolone 30 - 40 mg per os for 10-14 days
If cannot tolerate oral intake - the equivalent dose intravenously (up to 14 days)
Discuss the option of inhaled glucocorticoids by metered dose inhalator or nebulizer (after 
completion of treatment with systemic steroids)
Antibiotics (by indications)
Fig. 4. Treatment of severe exacerbations of COPD in the emergency department.
In severe exacerbations of COPD patients have to be hospitalized in an intensive care unit, the 
indication for which are:
1. evere shortness of breath, not releaved by bronchodilators.
2. Impaired consciousness, coma.
3. Progressive hypoxemia (PaO2 < 50 m Hg), hypercapnia (PaCO2 > 60 mm Hg) and/or
respiratory acidosis (pH < 7.25), despite the use of oxygen-therapy and noninvasive ventilation. 
Criteria for patient discharge from hospital after a COPD exacerbation:
a) requirement for inhaled short-acting adreno-agonists does not exceed more than every 4 hours. 
b) the patient can ambulate on their own, eat and sleep without frequent nighttime awakenings
from shortness of breath;
c) stable state for 12-24 hours;
d) stable blood gas analysis for 12-24 hours;
e) patient and responsible family members have a complete understanding of proper medication 
use
f) there are arrangements for further observation and treatment at home.
In the next 4-6 weeks the patient should be re-examined by a doctor to evaluate adaptation to
life and correct inhalation technique, as well as analysis of pulmonary function tests (PFT), blood 
gas or oxygen saturation (to decide if a long-term oxygen therapy is necessary). Further treatment 
may be indicated at this time. 
For the prevention of exacerbations bronchodilators and inhaled glucocorticoids are used in 
combination with long-acting β2-adrenomimetics (severe and very severe COPD). Yearly
influenza vaccination is highly recommended.
Fig. 4.  Treatment of severe exacerbations of COPD in the emergency department.
Bronchodilators
β2-adrenoreceptor agonists short-acting and/or ipratropium bromide by metered dose inhalator
with large volume spacer or via a nebulizer, administered "on demand"
When failure - perhaps intravenous theophylline
Discuss the possibility of appointing long-lasting bronchodilators if the patient had not received
these drugs previously
Glucocorticoids (dose may vary) Prednisone 30 – 40 mg per os during 10 – 14 days. Discuss the 
possibility of using inhaled glucocorticoids (after completing treatment course with systemic 
steroids)
Antibiotics (by indications)
Bronchodilators
β-adrenoreceptor agonists short-acting and/or ipratropium bromide by metered dose inhaler with
large volume spacer or nebulizer, administered "on demand"
When failure - perhaps intravenous theophylline
Oxygen therapy (at SaO2 * < 90%
Glucocorticoids
Prednisolone 30-40 mg by mouth for 10-14 days
If cannot tolerate oral intake - the equivalent intravenous dose (up to 14 days)
Discuss the option of inhaled glucocorticoids by metered dose inhaler or nebulizer (after 
completion of treatment with systemic steroids)
Antibiotics (by indications)
*Sa  –  blood Oxygen satur tion.
Check inhalation technique
Assess the level of education of patients
Fig. 3.  Treatment of moderate exacerbations of COPD in hospitalized patients.
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For the prevention of exacerbations bronchodilators 
and inhaled glucocorticoids are used in combination 
with long-acting β2-adrenomimetics (severe and very 
severe COPD).  Yearly influenza vaccination is highly 
recommended.
In conclusion, it should be noted that if the antibiotic 
therapy is chosen correctly for the individual, it reduces 
the duration of hospital stay and the costs associated with 
medical care.
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Abstract
The study involved 23 patients with decompensated liver cirrhosis and ascitic syndrome.  This trial was designed to determine the value of serum-
ascites and lymphatic albumin gradients.  We established diminution of the albumin ascites-lymphatic gradient in relationship with the evolution of the 
ascitic syndrome.  We introduce the notion of serum/ascites/lymphatic albumin gradient and its significance on parameters of the evolution of the ascitic 
syndrome.  It is required to validate the clinical application of the gradient in following studies.
Key words: ascitic syndrome, serum ascitic limphatic albumin gradient.
Изменения альбуминового градиента (асцит, плазма, лимфа)  
у декомпенсированных больных циррозом печени и асцитическим синдромом
В настоящую работу включены 23 больных с декомпенсированным циррозом печени и асцитическим синдромом.  Исследование было 
посвящено изучению и оценке альбуминового градиента (асцит, плазма, лимфа).  Установлено уменьшение альбуминового градиента асцит-
лимфа в соотношении с развитием асцитического синдрома.  Впервые предложена терминология альбуминового градиента (асцит, плазма, 
лимфа), однако его значение, как критерия развития асцитического синдрома, требует уточнения в дальнейших исследованиях.
Ключевые слова: асцитический синдром, градиент концентрации альбумина сыворотка-асцит.
Introduction
According to literature data, 4-5% of the global po-
pulation shows disturbances of liver functions, of which 
about 10-20% are caused by viral hepatitis, toxic hepatitis 
or ethanol alcohol, that within 10-20 years lead to the 
evolution of cirrhosis liver [1], which inevitably leads to 
a high rate of complications such as variceal hemorrhage 
either cirrhogenous hypersplenism with coagulopathy in 
progress or ascitic syndrome.  Thus, N. Fisher et al. notes 
that in Great Britain alone, during the years 1993-2000, 
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